Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases

Purpose: To evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. Experimental Design: Patients with relapsed and refractory lymphoproliferative diseases received perifosine (50 mg twice daily) for 1 month. Patients achieving less than partial response (PR) after perifosine alone were administered the combination therapy [perifosine plus sorafenib (400 mg twice daily)] until progressive disease (PD) or unacceptable toxicity occurred. The pERK and pAKT in peripheral blood lymphocytes as well as serum cytokine levels were investigated as predictive biomarkers of response. Results: Forty patients enrolled in this study. After 1 month of perifosine alone, 36 who achieved less than PR went on to combination therapy, whereas four patients with chronic lymphocytic leukemia (CLL) who achieved PR continued with perifosine alone for a median of 10 months (range, 4–21). The most common drug-related toxicities were grade 1–2 anemia (17%), thrombocytopenia (9%), diarrhea (25%), joint pain (22%), and hand–foot skin reaction (25%). Three patients experienced grade 3 pneumonitis. Eight patients (22%) achieved PR, 15 (42%) achieved stable disease, and 13 (36%) experienced PD. A 28% PR rate was recorded for 25 patients with Hodgkin lymphoma. Among all patients, median overall survival and progression-free survival were 16 and 5 months, respectively. Early reductions in pERK and pAKT significantly correlated with the probability of clinical response. Conclusions: Perifosine and sorafenib combination therapy is feasible with manageable toxicity and demonstrates promising activity in patients with Hodgkin lymphoma. The predictive value of pERK and pAKT should be confirmed in a larger patient cohort. Clin Cancer Res; 20(22); 5641–51. ©2014 AACR.

[1]  A. Anichini,et al.  Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts , 2013, Leukemia.

[2]  R. Gascoyne,et al.  A phase II study of sorafenib (BAY 43–9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404) , 2013, Journal of Hematology & Oncology.

[3]  A. Anichini,et al.  Phase II study of sorafenib in patients with relapsed or refractory lymphoma , 2012, British journal of haematology.

[4]  B. Evers,et al.  The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. , 2012, Anticancer research.

[5]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Gribben,et al.  Risk categories and refractory CLL in the era of chemoimmunotherapy. , 2012, Blood.

[7]  P. Zinzani,et al.  Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Nemunaitis,et al.  Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Jakubowiak,et al.  Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Trinkaus,et al.  A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. , 2011, Blood.

[11]  T. Choueiri,et al.  Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials. , 2011, Critical reviews in oncology/hematology.

[12]  A. Hagenbeek,et al.  Optimising the lymphoma response criteria in the era of targeted therapy. , 2011, The Lancet. Oncology.

[13]  E. Eisenhauer,et al.  Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group , 2011, Leukemia & lymphoma.

[14]  R. Ulrich,et al.  CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. , 2011, Blood.

[15]  D. Bedognetti,et al.  Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors , 2010, Clinical Cancer Research.

[16]  C. Carlo-Stella,et al.  Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience , 2010, Leukemia & lymphoma.

[17]  C. Carlo-Stella,et al.  Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up , 2010, Bone Marrow Transplantation.

[18]  T. Habermann,et al.  A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma , 2010, American journal of hematology.

[19]  A. Zelenetz,et al.  Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma , 2009, British journal of haematology.

[20]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[21]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[22]  N. Bartlett,et al.  Salvage regimens for Hodgkin lymphoma. , 2008, Clinical advances in hematology & oncology : H&O.

[23]  T. Barbui,et al.  Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[25]  R. Figlin,et al.  Phase I multicenter trial of perifosine in combination with sorafenib for patients with advanced cancers including renal cell carcinoma , 2008 .

[26]  G. Pond,et al.  A Phase 2 study of perifosine in advanced or metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[27]  P. Dent,et al.  The Kinase Inhibitor Sorafenib Induces Cell Death through a Process Involving Induction of Endoplasmic Reticulum Stress , 2007, Molecular and Cellular Biology.

[28]  W. Klapper,et al.  High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma , 2007, Leukemia.

[29]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Benson,et al.  A Phase II Trial of Perifosine in Locally Advanced, Unresectable, or Metastatic Pancreatic Adenocarcinoma , 2007, American journal of clinical oncology.

[31]  D. Ettinger,et al.  Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma , 2006, Cancer.

[32]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[33]  Hiroshi Yasui,et al.  Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. , 2005, Blood.

[34]  G. Gores,et al.  The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.

[35]  S. Steinberg,et al.  A phase II study of perifosine in androgen independent prostate cancer , 2005, Cancer biology & therapy.

[36]  L. Young,et al.  Constitutive activation of phosphatidyl‐inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR , 2005, The Journal of pathology.

[37]  J. Sebolt-Leopold,et al.  Targeting the mitogen-activated protein kinase cascade to treat cancer , 2004, Nature Reviews Cancer.

[38]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[39]  L. Goodglick,et al.  Inhibition of the Raf–MEK1/2–ERK1/2 Signaling Pathway, Bcl-xL Down-Regulation, and Chemosensitization of Non-Hodgkin’s Lymphoma B Cells by Rituximab , 2004, Cancer Research.

[40]  T. McDonnell,et al.  MCL-1 expression in B-cell non-Hodgkin's lymphomas. , 2004, Human pathology.

[41]  Suzanne Cory,et al.  The Bcl-2 family: roles in cell survival and oncogenesis , 2003, Oncogene.

[42]  E. Sausville,et al.  Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. , 2003, Molecular cancer therapeutics.

[43]  Garry P. Nolan,et al.  Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry , 2002, Nature Biotechnology.

[44]  Ulrich Siebenlist,et al.  Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.

[45]  D. Hedley,et al.  Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors. , 2001, Cytometry.

[46]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[47]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[48]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[49]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[50]  E. Petricoin,et al.  Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.